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TBackground: Selective inhibition of cyclooxygenase 2 has been reported to have not
only anti-inflammatory effects but also effects on the immune response. We inves-
tigated ability of a cyclooxygenase 2 inhibitor to inhibit alloimmune response in a
murine cardiac transplantation model.
Methods: CBA (H2k) mice underwent transplantation of C57BL/10 (H2b) hearts. On
the day of transplantation, the recipients received either no treatment or single
administration of aspirin (a cyclooxygenase 1 and 2 inhibitor) or the selective
cyclooxygenase 2 inhibitor NS-398. Naive CBA mice (secondary recipients) un-
derwent adoptive transfer of splenocytes from treated mice with long-surviving
grafts (primary recipients) to determine whether regulatory cells developed after
NS-398 treatment. Histologic, cell-proliferation, and cytokine studies were also
performed.
Results: Untreated CBA mice rejected C57BL/10 cardiac grafts acutely (median
survival time, 8 days). The majority of recipients given aspirin rejected their grafts
within 20 days (median survival time, 11 days). In mice given NS-398, the majority
of the grafts survived indefinitely (median survival time, 100 days). Secondary
CBA recipients given CD4 splenocytes from primary CBA recipients treated with
NS-398 also had indefinite survival of C57BL/10 hearts (median survival time,60
days). Graft acceptance and proliferative hyporesponsiveness were also confirmed
by the histologic and cell-proliferation studies, respectively. Production of interleu-
kin 4 and 10 from splenocytes of the recipients treated with NS-398 were signifi-
cantly higher than that from untreated recipients.
Conclusions: In our model administration of cyclooxygenase 2 inhibitor induced
indefinite survival of fully mismatched cardiac grafts and generated CD4 regula-
tory cells. Cyclooxygenase 2 inhibitor could warrant consideration for use as an
immunomodulating agent in clinical transplantation.
Transplantation has become an accepted treatment for patients with end-stageorgan failure. However, clinical success of organ transplantation has beenachieved through the use of nonspecific immunosuppressive drugs to inhibit
immune responses. These drugs generally need to be given for the life of the
transplant and have many potential direct side effects, as well as increased risk of
life-threatening complications, such as cardiovascular disease, infections, and ma-
lignancies.1
Prostaglandins (PGs), which are bioactive substances synthesized from arachi-
donic acids, are lipid inflammatory mediators that play central roles in modulating
the immune response by means of complex interactions with leukocytes and
parenchymal cells in inflamed organs.2 Cyclooxygenase (COX) is a key enzyme for
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TXsynthesis of PGs and has at least 2 isoforms. The constitu-
tive isoform, COX-1, exists in nearly all types of cells at a
constant level and provides PGs in the gastric mucosa to
maintain integrity of the mucosal epithelium and thrombox-
ane A2 in platelets to mediate hemostasis by means of
platelet aggregation. In contrast, the COX-2 isoform is
normally absent from cells but is induced dramatically by
cytokines, tumor promoters, and mitogens on stimulation,
especially in cells in the immune system, demonstrating that
COX-2 can be involved in PG formation in inflammatory
processes.
Highly selective COX-2 inhibitors should produce an-
ti-inflammatory activity while eliminating the principal
side effects associated with use of nonsteroidal anti-
inflammatory agents.3 Some studies have shown that
COX-2 inhibitors might have other important therapeutic
effects, such as preventing the development or progression
of colorectal cancer4,5 and slowing cognitive decline in
Alzheimer’s disease.6 One transplantation investigation
found that administration of PGE2 induced modest prolon-
gation of rat cardiac allografts.7 On the other hand, treat-
ment with aspirin, a COX-1 and COX-2 inhibitor, induced
moderate prolongation of survival of cardiac allografts in
rats.8 Moreover, COX-2 has been shown to be important in
allograft rejection in both experimental and clinical trans-
plantation. In a rat model of cardiac transplantation, COX-2
expression was significantly higher in allografts than in
syngeneic grafts.9 Examinations of COX-2 expression in
biopsy specimens from transplanted kidneys in human sub-
jects found upregulation of COX-2 in allografts being re-
jected.10
In this study we investigated the effects of selective
inhibition of COX-2 on graft survival i n a m urine model of
cardiac transplantation. We used the compound N-(2-
cyclohexyl-4-nitrophenyl) methane sulfonamide (NS-398),
which specifically inhibits COX-2 activity without affecting
COX-1.11,12 We found that a single dose of NS-398 given
on the day of transplantation induced indefinite survival
of fully mismatched cardiac allografts and generated
CD4 regulatory cells. Selective inhibition of COX-2 is
widely used clinically for postoperative treatment of in-
flammatory processes, and our results suggest that
COX-2 inhibitors also have the potential to be used as
immunomodulatory agents to prevent rejection of allo-
grafts and drug-related toxicity of general immunosup-
pressants in patients.
Materials and Methods
Animals and Transplantation
Male C57BL/10 (H2b), CBA (H2k), and BALB/c (H2d) mice were
purchased from Sankyo Ltd (Tokyo, Japan), housed in conven-
tional facilities at the Biomedical Services Unit of Teikyo Univer-
sity, and used in this study when 8 to 12 weeks old in accordance
with the guidelines of the Animal Use and Care Committee of
1168 The Journal of Thoracic and Cardiovascular Surgery ● OctTeikyo University. All transplantation procedures were performed
with the mice after achievement of general anesthesia. Fully vas-
cularized heterotopic hearts from C57BL/10 donors were trans-
planted into CBA recipients by using microsurgical techniques.13
Postoperatively, graft function was assessed by palpating the heart
for evidence of contraction. Rejection was defined as complete
cessation of contraction and confirmed by means of direct visual-
ization and histologic examination of the graft. In some experi-
ments, full-thickness skin grafts (approximately 1 cm2) were trans-
planted on the dorsal thorax of recipient mice and secured with an
adhesive bandage for 7 days. Rejection was defined as the com-
plete loss of viable epidermal graft tissue.
Experiment 1: Allograft Survival in NS-398–treated
Recipients
On the day of transplantation, recipient mice were given either no
drug treatment or a subcutaneous injection of one 20-mg dose of
aspirin (a COX-1 and COX-2 inhibitor), dimethyl sulfoxide
(DMSO; vehicle alone), or various doses of NS-398 (Cayman
Chemical, Ann Arbor, Mich). Before administration, the NS-398
was dissolved in DMSO and diluted with phosphate-buffered
saline in a 2:3 solution of DMSO/phosphate-buffered saline (pH
7.2).
Histologic Studies of Harvested Grafts
Cardiac grafts transplanted into untreated mice and mice given
NS-398 were removed 7 and 100 days after transplantation and
studied histologically. The specimens were immersion fixed in 5%
neutral buffered formalin and embedded in paraffin by using
routine procedures. Paraffin sections (4-m thick) were cut,
mounted on sialine-coated slides, and stained with hematoxylin
and eosin. Graft histology was assessed by using the International
Society for Heart Transplantation Standardized Grading System,14
and transplant vasculopathy was assessed by scoring Elastica van
Gieson–stained arteries as follows: less than 5% occlusion, grade
0; greater than 5% to 20% occlusion, grade 1; greater than 20% to
40% occlusion, grade 2; greater than 40% to 60% occlusion, grade
3; greater than 60% to 80% occlusion, grade 4; and greater than
80% to 100% occlusion, grade 5.15
Experiment 2: Adoptive Transfer Studies
Adoptive transfer studies were conducted to determine whether
regulatory cells were generated after treatment with NS-398. One
hundred days after CBA recipients (primary recipients) received
transplantation of C57BL/10 cardiac allograft with administration
of NS-398, splenocytes (5 107) from the primary recipients with
functioning allografts were adoptively transferred into naive CBA
mice (secondary recipients). The secondary recipients underwent
transplantation of C57BL/10 hearts immediately after the adoptive
transfer. In some experiments, CD4 cells were purified from the
spleen in the primary recipients by means of positive selection
with MACS CD4 Microbeads (Miltenyi Biotec Inc, Auborn, Calif;
purity, 98%), and 2  107 of the CD4 cells were adoptively
transferred into naive secondary recipients that received transplan-
tation of C57BL/10 hearts immediately afterward.
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TXExperiment 3: Cell-proliferation, Cytokine, and
Immunohistochemistry Studies
In mixed leukocyte culture studies the responder cells were spleno-
cytes from naive CBA mice or from untreated or NS-398–treated
CBA mice that had undergone transplantation of a C57BL/10 heart
7 days earlier. Stimulator cells were C57BL/10 (allogeneic) or
CBA (syngeneic) splenocytes treated with 100 g/mL mitomycin
C (Kyowa Hakko, Osaka, Japan) for 30 minutes at 37°C. The
responder cells (0.25  106) were cocultured with the stimu-
lator cells (1  106) in complete medium in a humidified 5%
CO2 atmosphere (CH-16M; Hitachi, Tokyo, Japan) at 37°C in
96-well, flat-bottomed, tissue-culture plates (Iwaki Scitech Di-
vision, Tokyo, Japan) for 3 to 6 days.16 Proliferation was
assessed by using an enzyme-linked immunosorbent assay for
bromodeoxyuridine incorporation (Biotrak, version 2; Amer-
sham, Little Chalfont, United Kingdom),16,17 according to the
manufacturer’s instructions.
An enzyme-linked immunosorbent assay was also performed to
assess levels of interleukin (IL) 2, IL-4, IL-10, and interferon
(IFN)- in the supernatant of the mixed leukocyte culture on day
4. The capture monoclonal antibody (mAb; JES5-2A5), detection
mAb (JES5-16E3), and recombinant standard for IL-10 were from
BD PharMingen (San Diego, Calif). The capture and detection
mAbs for IL-2 (JES6-1A12 and JES6-5H4, respectively), IL-4
(BVD-1D11 and BVD-24G2, respectively), and IFN- (R4-6A2
and XMG1.2, respectively) were from Caltag Laboratories (Bur-
lingame, Calif). Recombinant standards for IL-2, IL-4, and IFN-
were from PeproTech (London, United Kingdom).
In the immunohistochemistry studies immunolabeling was per-
formed on 4-m-thick, paraffin-embedded coronal sections of
cardiac allografts fixed in Bouin solution (Medical Chemical Corp,
Torrance, Calif). After deparaffinization, endogenous peroxidase
activity was quenched with 0.3% H2O2-methanol for 20 minutes.
Nonspecific binding of the antibody was blocked with the Non-
Specific Staining Blocking Reagent (DakoCytomation Co. Ltd.,
Kyoto, Japan) for 10 minutes, followed by incubation with poly-
clonal rabbit anti-COX-2 antibody (Cayman) at room temperature
for 1 hour. Thereafter, sections were incubated for 30 minutes at
room temperature with the secondary biotinylated goat anti-rabbit
immunoglobulin G antibody (Vector Labs, Burlingame, Calif).
After washing with 0.05 M Tris-HCl, the sections were incubated
with avidin-biotin-peroxidase complexes (Vector Labs) for 30
TABLE 1. Survival of C57BL/10 cardiac grafts in treated CB
Group Treatment* Gra
1 None 5, 7, 7, 8, 9, 9, 9
2 DMSO 7, 7, 7, 10, 11
3 Aspirin (20 mg/kg) 7, 8, 9, 11, 12, 1
4 NS-398 (20 mg/kg) 40, 54, 54, 55, 6
5 NS-398 (2 mg/kg) 11, 11, 18, 22, 2
6 NS-398 (0.2 mg/kg) 6, 8, 8, 8, 22
7 NS-398 (200 mg/kg) 1,‡ 1,‡ 1,‡ 3, 3,
MST, Median survival time; DMSO, dimethyl sulfoxide (control vehicle); N
received transplantation of C57BL/10 hearts with a single administration o
U test. ‡Recipients died with beating cardiac grafts.minutes at room temperature, and peroxidase activity was demon-
The Journal of Thoracicstrated with 3,3= diaminobenzidine. Rabbit immunoglobulin G was
used as a negative control. Sections were counterstained with
Meyer’s hematoxylin.
Statistical Analysis
The allograft survival in 2 groups was compared by using Mann-
Whitney U tests (StatView SE  Graphics; Abacus Concepts,
Cary, NC). In the cell-proliferation and cytokine studies, 2 groups
were compared by using unpaired Student t tests (StatView SE 
Graphics).
Results
Experiment 1: NS-398–induced Prolongation of
Allograft Survival in a Dose-dependent Manner
CBA mice given either no treatment or DMSO (control
vehicle) at transplantation rejected C57BL/10 cardiac grafts
acutely (median survival time [MST], 8 and 7 days, respec-
tively; Table 1, group 1 and 2). Mice given aspirin had
slightly prolonged allograft survival (MST, 11 days; n  7;
Table 1, group 3). The majority of the mice given 20 mg/kg
NS-398 had indefinite graft survival (MST,  100 days; n
 26; Table 1, group 4; P  .0001 vs DMSO [control
vehicle]). On the other hand, when the recipients were
treated with 2 mg/kg NS-398, they had only modest pro-
longation of allograft survival (MST, 18 days; n  5; Table
1, group 5). When treated with 0.2 mg/kg, prolongation of
allograft survival was not observed (MST, 8 days; Table 1,
group 6). When treated with 200 mg/kg NS-398, the allo-
grafts were also rejected acutely, with an MST 3 days,
because 200 mg/kg NS-398 might be toxic to the recipients
and allografts (Table 1, group 7). Three other recipients in
the group receiving 200 mg/kg NS-398 died 1 day after
transplantation bearing beating cardiac grafts. These data
suggest that a single dose of NS-398 induced unrespon-
siveness to fully mismatched cardiac allograft in a dose-
dependent manner. Histologic examinations of cardiac
grafts harvested 100 days after transplantation (Figure 1, A;
grade 0-1A) showed that the C57BL/10 grafts in CBA mice
treated with NS-398 were similar to syngeneic grafts (Fig-
ecipients
vival (d) MST (d) P value†
8
7 NS vs 1
11 NS vs 1
94, 94, 100   18 100 .0001 vs 2
18 .05 vs 2
8
4 3
t significant; vs 1, versus group 1; vs 2, versus group 2. *CBA recipients
398 or control substances (aspirin or dimethyl sulfoxide). †Mann-WhitneyA r
ft sur
4, 22
5, 79,
2
3, 4,
S, no
f NS-ure 1, B), with only a few infiltrating leukocytes and no
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grade 0). Interestingly, at 7 days after transplantation (Fig-
ure 1, C; grade 0-1B), many leukocytes were observed
infiltrating the allografts in mice given NS-398, indicating
that the anti-inflammatory effect of the agent was not com-
pletely operative in our model.
To determine whether the unresponsiveness induced in
the CBA recipients with 20 mg/kg NS-398 was donor
specific, we conducted a second challenge of skin grafting
to the recipients with long-surviving cardiac allografts after
NS-398 treatment. One hundred days after transplantation,
these mice were given donor-specific (C57BL/10) or third-
party (BALB/c) skin grafts. The donor-specific skin grafts
had significantly longer survivals than the third-party skin
grafts (MST, 14 and 11 days, respectively; n  5; P  .05,
data not shown), indicating that the unresponsiveness might
be donor specific. The donor specificity was also confirmed
by using the mixed leukocyte culture assay (data not
shown).
Experiment 2: NS-398 Treatment Generated
Regulatory Cells
In the adoptive transfer studies secondary CBA recipients
given adoptive transfer of splenocytes from the primary recip-
Figure 1. Histologic studies of harvested cardiac gra
immunostaining (E-H). A, C57BL/10 allograft obtained 1
mg/kg NS-398 the day of transplantation. B, CBA graft
after transplantation. C, C57BL/10 allograft harvested
plantation. D, C57BL/10 allograft harvested from an unt
for positive control). (Hematoxylin and eosin stain; or
chemistry studies of harvested cardiac allografts for c
from an untreated CBA recipient 7 days after transplan
harvesting from donor C57BL/10 mice. G, C57BL/10 allo
days after transplantation. H, C57BL/10 allograft harve
transplantation (cyclooxygenase-positive leukocytes [ients with 20 mg/kg NS-398 had prolonged survival of
1170 The Journal of Thoracic and Cardiovascular Surgery ● OctC57BL/10 hearts (Figure 2, A; MST, 62 days; n  5) but
rejected third-party (BALB/c) allografts acutely (survival time,
8, 12, 14, 17, and 38 days; MST, 14 days). In contrast,
secondary CBA recipients given adoptive transfer of spleno-
cytes from naive CBA mice (control group) rejected
C57BL/10 hearts acutely (MST, 9 days; n  7). When CD4
cells were purified from the primary recipients with NS-398
treatment and were adoptively transferred into naive secondary
recipients, all allografts in the secondary recipients survived
indefinitely (Figure 2, B; n  5; P  .01 compared with that
in the control group). Adoptive transfer of CD4 cells that
were purified from naive CBA mice did not induce graft
prolongation (MST, 12 days; n  5). These data suggest that
NS-398 treatment induced CD4 regulatory cells.
Experiment 3: Cell-proliferation, Cytokine, and
Immunohistochemistry Studies
Maximum proliferation of naive CBA splenocytes (responder
cells) against C57BL/10 splenocytes (stimulator cells) treated
with mitomycin C occurred on day 4 of the mixed leukocyte
culture. Proliferation of splenocytes from CBA mice given
NS-398 was significantly reduced compared with that of
splenocytes from untreated mice or naive CBA mice (Figure 3,
ith hematoxylin and eosin staining (A-D) and COX-2
ys after transplantation from a CBA recipient given 20
eneic graft) harvested from a CBA recipient 100 days
an NS-398–treated CBA recipient 7 days after trans-
d CBA recipient 7 days after transplantation (showing
l magnification 50 and 100 [inset].) Immunohisto-
oxygenase 2 staining. E, C57BL/10 allograft harvested
. F, C57BL/10 cardiac graft obtained immediately after
t harvested from an NS-398–treated CBA recipient 14
from an NS-398–treated CBA recipient 30 days after
s]). (Original magnification 300.)fts, w
00 da
(syng
from
reate
igina
yclo
tation
graf
sted
arrowA).
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TXFigure 2. A, Graft survival after adoptive transfer of splenocytes. CBA mice (primary recipients) were treated with
20 mg/kg NS-398 and underwent transplantation of C57BL/10 cardiac grafts the same day. One hundred days later,
splenocytes (5 107) from the primary recipients with functioning allografts were adoptively transferred into naive
CBA mice (secondary recipients) that were then given C57BL/10 cardiac grafts. Secondary recipients in the control
group underwent adoptive transfer of splenocytes from naive CBA mice (#P < .01 between the 2 groups). B, Graft
survival after adoptive transfer of CD4 cells. CBA mice (primary recipients) were treated with 20 mg/kg NS-398
and underwent transplantation of C57BL/10 cardiac grafts the same day. One hundred days later, CD4 cells were
purified from the spleen in the primary recipients with functioning allografts by using positive selection with MACS
CD4 Microbeads, and 2 107 CD4 cells were adoptively transferred into naive secondary recipients that received
transplantation of C57BL/10 hearts immediately afterward.
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splenocytes from mice treated with NS-398 were significantly
higher than those in splenocytes from untreated mice or in
syngeneic splenocytes. There were no differences between
groups in levels of IL-2 or IFN- (data not shown).
Results of the immunohistochemistry studies are shown in
Figure 1. COX-2 expression was observed mainly on leuko-
Figure 3. A, Results of cell-proliferation assay in mixe
with NS-398 (20 mg/kg) were given cardiac grafts from
cells) from the CBA mice (responder cells) were cocultu
cells; 1  106 cells) (#P < .01 between 2 groups). B a
Untreated CBA mice and mice treated with NS-398 (20 m
days later, splenocytes (0.25  106 cells) from the CBA
from either C57BL/10 mice (stimulator cells; 1  106 ce
10 (IL-10; C), interleukin 2, and interferon  in the mixe
immunosorbent assays. There were no differences betw
shown; #P < .01 and ##P < .05 between 2 groups).cytes, such as polymorphonuclear leukocytes and monocytes.
1172 The Journal of Thoracic and Cardiovascular Surgery ● OctIn untreated mice that underwent transplantation of allograft,
COX-2 expression in their cardiac grafts was already upregu-
lated on day 7 after transplantation (Figure 1, E), whereas no
COX-2 expression was observed in hearts from naive mice
(Figure 1, F). In mice given NS-398 (20 mg/kg), COX-2
expression in the allografts was not detected from day 7
through day 14 after transplantation (Figure 1, G). On day 30
kocyte culture. Untreated CBA mice and mice treated
BL/10 mice. Seven days later, splenocytes (0.25  106
with splenocytes from either C57BL/10 mice (stimulator
, Levels of cytokines in the mixed leukocyte culture.
) were given cardiac grafts from C57BL/10 mice. Seven
e (responder cells) were cocultured with splenocytes
for 4 days. Levels of interleukin 4 (IL-4; B), interleukin
kocyte culture were assessed by using enzyme-linked
groups in interleukin 2 or interferon  levels (data notd leu
C57
red
nd C
g/kg
mic
lls)
d leu
eenafter transplantation, however, COX-2 expression had returned
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mice (Figure 1, H). These data suggest that the anti-inflamma-
tory effect (suppression of COX-2) of NS-398 was temporary,
even though the hyporesponsiveness induced by the treatment
continued until day 100 after transplantation.
Discussion
In this study treatment with a single dose of a selective
COX-2 inhibitor, NS-398, induced indefinite survival of
fully allogeneic grafts in a murine model of cardiac trans-
plantation. In the majority of mice given the optimal dose of
this agent (20 mg/kg), no evidence of either acute or chronic
rejection was observed. Treatment with NS-398 also re-
sulted in generation of regulatory cells by 100 days after
transplantation, and these cells had suppressive activity in a
mixed leukocyte culture. Furthermore, splenocytes from
mice given NS-398 had increased levels of IL-4 and IL-10
in a mixed leukocyte culture. CD4 cells were one of the
regulatory populations.
Recently, Ma and associates18 found that daily adminis-
tration of another COX-2 inhibitor reduced leukocyte infil-
tration and apoptosis of cardiomyocytes by nitric oxide in a
rat model of cardiac transplantation, although survival of the
allografts was only slightly prolonged. On the other hand,
our study showed that a single administration of NS-398 on
the day of transplantation induced indefinite survival of
allografts in the majority of the recipients, suggesting that
other mechanisms contribute to the long-term acceptance of
the allograft in our study.
The mechanisms of allograft unresponsiveness have
been classified as deletion, anergy, and immune regula-
tion.19 In our study, when the secondary naive CBA recip-
ients were adoptively transferred with 5  107 splenocytes
from the CBA recipients with functioning C57BL/10 allo-
grafts after NS-398 treatment, the secondary recipients ac-
cepted C57BL/10 cardiac allografts. Furthermore, all grafts
survived indefinitely in the secondary recipients, with adop-
tive transfer of CD4 cells from the primary recipients with
NS-398 treatment. These data demonstrated that CD4 reg-
ulatory cells were generated after NS-398 treatment and that
immune regulation might be involved in one of the mech-
anisms to permit long-term acceptance of the allograft by
NS-398 treatment. However, donor-specific skin grafts as a
second challenge were eventually rejected, suggesting that
NS-398 treatment did not induce transplantation tolerance.
One possibility is that the number, function, or both of the
regulatory cells might not be sufficient for inducing indef-
inite survival of second challenge of the donor-specific skin
grafts.
On 100 days after transplantation in our study, the his-
tologic findings in the cardiac allografts in the mice given
NS-398 were similar to those in syngeneic grafts. However,
our immunohistochemistry assessments indicated that the
The Journal of Thoracicanti-inflammatory effect (ie, suppression of COX-2) of a
single dose of NS-398 on the day of transplantation was
temporary because COX-2 cells were detected infiltrating
into the allograft around 30 days after transplantation. These
data might indicate that the hyporesponsiveness induced by
NS-398 have resulted from immunomodulatory, rather than
anti-inflammatory, activity, leading to the subsequently in-
ducing regulatory cells, although NS-398 might have other
capacities as an immunosuppressive agent that are unrelated
to COX-2 inhibition.
In some previous studies, aspirin or a COX-2 inhibitor
was found to regulate the maturation of murine20 and hu-
man21 dendritic cells, and aspirin administration resulted in
an impairment of the ability of dendritic cells to stimulate
T-cell responses in vivo. In our study splenocytes from mice
given NS-398 produced higher levels of both IL-4 and
IL-10 in a mixed leukocyte culture 7 days after transplan-
tation of cardiac allografts than those produced by spleno-
cytes from untreated transplant recipients. IL-10 is a prin-
cipal regulatory cytokine in the maturation of dendritic
cells.22 Moreover, under some circumstances, IL-10, IL-4,
or both were observed to be required for the induction or
function of regulatory cells in autoimmunity23,24 or trans-
plantation25,26 models. These findings and the results of our
adoptive transfer studies indicate that treatment with NS-
398 might inhibit immunologic responses against allografts
by means of IL-4 and IL-10, presumably through inhibition
of dendritic cell maturation in the induction phase of hypo-
responsiveness and through generation of regulatory cells in
the maintenance phase.
In summary, we found that the COX-2 inhibitor NS-398
had an immunomodulatory effect that induced indefinite
survival of cardiac allografts, as well as having an anti-
inflammatory effect. We also showed that treatment with
NS-398 generated CD4 regulatory cells in our model. In
patients, nonsteroidal anti-inflammatory agents, including
COX-2 inhibitors, are commonly used for pain control after
surgical intervention. Therefore NS-398 might have the
potential to be clinically useful after organ transplantation
as adjuvant therapy given with conventional nonspecific
immunosuppressive agents to allow a reduction in the total
dose of those agents, thereby possibly preventing such side
effects as direct drug toxicity, infection, and malignant
disease. Testing of this strategy in a large-animal model is
warranted.
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